14371-77-8

Upstream product

• 3209-22-1 1,2-Dichloro-3-nitrobenzene 

Downstream Products

• 103921-05-7 3-(2-Chloro-6-nitro-phenylsulfanyl)-2-hydroxy-3-(4-methoxy-phenyl)-propionic acid methyl ester 
• 1247021-56-2 1-methylethyl 4-{2-[(2-chloro-6-nitrophenyl)sulfanyl]-3-ethoxy-3-oxopropyl}benzoate 
• 100902-59-8 (S)-1-(Naphthalene-2-sulfonyl)-pyrrolidine-2-carboxylic acid (2S,3S)-9-chloro-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester 
• 100938-15-6 (S)-1-(Naphthalene-2-sulfonyl)-pyrrolidine-2-carboxylic acid (2R,3R)-9-chloro-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester 
• 130695-87-3 Acetic acid (2R,3R)-9-chloro-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester 
• 103921-09-1 Acetic acid 9-chloro-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester 
• 103921-10-4 (+)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-9-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one 
• 103920-95-2 (2R,3R)-9-Chloro-5-(2-dimethylamino-ethyl)-3-hydroxy-2-(4-methoxy-phenyl)-2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-one 
• 103921-00-2 (+)-cis-2-(4-methoxyphenyl)-3-hydroxy-5-[2-(dimethylamino)ethyl]-9-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one 
• 103920-97-4 9-Chloro-5-(2-dimethylamino-ethyl)-3-hydroxy-2-(4-methoxy-phenyl)-2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-one 
• 103921-07-9 3-(2-Amino-6-chloro-phenylsulfanyl)-2-hydroxy-3-(4-methoxy-phenyl)-propionic acid 
• 100902-58-7 (+/-)-cis-9-chloro-2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one 
• 100902-60-1 (-)-cis-(2R,3R)-9-chloro-2,3-dihydro-3-hydroxy-2-(4'-methoxyphenyl)-1,5-benzothiazepin-4-[5H]-one 
• 100902-62-3 (+)-cis-(2S,3S)-9-chloro-2,3-dihydro-3-hydroxy-2-(4'-methoxyphenyl)-1,5-benzothiazepin-4-[5H]-one 

Relevant academic research and scientific papers

EP2/4 AGONISTS

EP2/4 compounds having improved dual pharmacological activity are described. The uniqueness of using EP2/4 dual agonists resides in their ability to modify both uveoscleral outflow via the ciliary muscle and conventional outflow via trabecular meshwork and Schlemm's canal all in the same treatment paradigm. The compounds can be employed for the treatment of glaucoma and ocular hypertension. Formula (I).

THE SYNTHESIS OF o-NITROBENZENETHIOLS: AN ADVANTAGEOUS NUCLEOPHILIC DISPLACEMENT ON o-CHLORONITROBENZENES

Reaction of substituted o-chloronitrobenzenes with sodium sulphide in DMSO occurs rapidly and gives the corresponding o-nitrobenzenethiols, following a convenient one-step pathway.Better yields are obtained when stoicheiometric amounts of sulphur, dissolved in a little carbon disulphide, are added in the presence of ethyl methyl ketone as solvent.